array(4) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(3)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
}
array(6) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(3)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
  ["paged"]=>
  int(1)
  ["meta_query"]=>
  NULL
}
object(WP_Query)#8501 (56) {
  ["query"]=>
  array(6) {
    ["posts_per_page"]=>
    string(1) "5"
    ["cat"]=>
    int(3)
    ["p"]=>
    string(0) ""
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(1)
    ["meta_query"]=>
    NULL
  }
  ["query_vars"]=>
  array(62) {
    ["posts_per_page"]=>
    int(5)
    ["cat"]=>
    int(6)
    ["p"]=>
    int(0)
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(1)
    ["meta_query"]=>
    array(0) {
    }
    ["error"]=>
    string(0) ""
    ["m"]=>
    string(0) ""
    ["post_parent"]=>
    string(0) ""
    ["subpost"]=>
    string(0) ""
    ["subpost_id"]=>
    string(0) ""
    ["attachment"]=>
    string(0) ""
    ["attachment_id"]=>
    int(0)
    ["name"]=>
    string(0) ""
    ["static"]=>
    string(0) ""
    ["pagename"]=>
    string(0) ""
    ["page_id"]=>
    int(0)
    ["second"]=>
    string(0) ""
    ["minute"]=>
    string(0) ""
    ["hour"]=>
    string(0) ""
    ["day"]=>
    int(0)
    ["monthnum"]=>
    int(0)
    ["year"]=>
    int(0)
    ["w"]=>
    int(0)
    ["category_name"]=>
    string(14) "nota-de-prensa"
    ["tag"]=>
    string(0) ""
    ["tag_id"]=>
    string(0) ""
    ["author"]=>
    string(0) ""
    ["author_name"]=>
    string(0) ""
    ["feed"]=>
    string(0) ""
    ["tb"]=>
    string(0) ""
    ["comments_popup"]=>
    string(0) ""
    ["meta_key"]=>
    string(0) ""
    ["meta_value"]=>
    string(0) ""
    ["preview"]=>
    string(0) ""
    ["s"]=>
    string(0) ""
    ["sentence"]=>
    string(0) ""
    ["fields"]=>
    string(0) ""
    ["menu_order"]=>
    string(0) ""
    ["category__in"]=>
    array(0) {
    }
    ["category__not_in"]=>
    array(0) {
    }
    ["category__and"]=>
    array(0) {
    }
    ["post__in"]=>
    array(0) {
    }
    ["post__not_in"]=>
    array(0) {
    }
    ["tag__in"]=>
    array(0) {
    }
    ["tag__not_in"]=>
    array(0) {
    }
    ["tag__and"]=>
    array(0) {
    }
    ["tag_slug__in"]=>
    array(0) {
    }
    ["tag_slug__and"]=>
    array(0) {
    }
    ["post_parent__in"]=>
    array(0) {
    }
    ["post_parent__not_in"]=>
    array(0) {
    }
    ["author__in"]=>
    array(0) {
    }
    ["author__not_in"]=>
    array(0) {
    }
    ["ignore_sticky_posts"]=>
    bool(false)
    ["cache_results"]=>
    bool(true)
    ["update_post_term_cache"]=>
    bool(true)
    ["update_post_meta_cache"]=>
    bool(true)
    ["post_type"]=>
    string(0) ""
    ["nopaging"]=>
    bool(false)
    ["comments_per_page"]=>
    string(2) "50"
    ["no_found_rows"]=>
    bool(false)
    ["order"]=>
    string(4) "DESC"
  }
  ["tax_query"]=>
  object(WP_Tax_Query)#8040 (6) {
    ["queries"]=>
    array(1) {
      [0]=>
      array(5) {
        ["taxonomy"]=>
        string(8) "category"
        ["terms"]=>
        array(1) {
          [0]=>
          int(6)
        }
        ["field"]=>
        string(7) "term_id"
        ["operator"]=>
        string(2) "IN"
        ["include_children"]=>
        bool(true)
      }
    }
    ["relation"]=>
    string(3) "AND"
    ["table_aliases":protected]=>
    array(1) {
      [0]=>
      string(21) "wp_term_relationships"
    }
    ["queried_terms"]=>
    array(1) {
      ["category"]=>
      array(2) {
        ["terms"]=>
        array(1) {
          [0]=>
          int(6)
        }
        ["field"]=>
        string(7) "term_id"
      }
    }
    ["primary_table"]=>
    string(8) "wp_posts"
    ["primary_id_column"]=>
    string(2) "ID"
  }
  ["meta_query"]=>
  object(WP_Meta_Query)#8039 (9) {
    ["queries"]=>
    array(0) {
    }
    ["relation"]=>
    NULL
    ["meta_table"]=>
    NULL
    ["meta_id_column"]=>
    NULL
    ["primary_table"]=>
    NULL
    ["primary_id_column"]=>
    NULL
    ["table_aliases":protected]=>
    array(0) {
    }
    ["clauses":protected]=>
    array(0) {
    }
    ["has_or_relation":protected]=>
    bool(false)
  }
  ["date_query"]=>
  bool(false)
  ["post_count"]=>
  int(5)
  ["current_post"]=>
  int(-1)
  ["in_the_loop"]=>
  bool(false)
  ["comment_count"]=>
  int(0)
  ["current_comment"]=>
  int(-1)
  ["found_posts"]=>
  string(3) "240"
  ["max_num_pages"]=>
  float(48)
  ["max_num_comment_pages"]=>
  int(0)
  ["is_single"]=>
  bool(false)
  ["is_preview"]=>
  bool(false)
  ["is_page"]=>
  bool(false)
  ["is_archive"]=>
  bool(true)
  ["is_date"]=>
  bool(false)
  ["is_year"]=>
  bool(false)
  ["is_month"]=>
  bool(false)
  ["is_day"]=>
  bool(false)
  ["is_time"]=>
  bool(false)
  ["is_author"]=>
  bool(false)
  ["is_category"]=>
  bool(true)
  ["is_tag"]=>
  bool(false)
  ["is_tax"]=>
  bool(false)
  ["is_search"]=>
  bool(false)
  ["is_feed"]=>
  bool(false)
  ["is_comment_feed"]=>
  bool(false)
  ["is_trackback"]=>
  bool(false)
  ["is_home"]=>
  bool(false)
  ["is_404"]=>
  bool(false)
  ["is_comments_popup"]=>
  bool(false)
  ["is_paged"]=>
  bool(false)
  ["is_admin"]=>
  bool(false)
  ["is_attachment"]=>
  bool(false)
  ["is_singular"]=>
  bool(false)
  ["is_robots"]=>
  bool(false)
  ["is_posts_page"]=>
  bool(false)
  ["is_post_type_archive"]=>
  bool(false)
  ["query_vars_hash":"WP_Query":private]=>
  string(32) "978a4dbf4a30d01d2492a794cf24d8a5"
  ["query_vars_changed":"WP_Query":private]=>
  bool(true)
  ["thumbnails_cached"]=>
  bool(false)
  ["stopwords":"WP_Query":private]=>
  NULL
  ["compat_fields":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(15) "query_vars_hash"
    [1]=>
    string(18) "query_vars_changed"
  }
  ["compat_methods":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(16) "init_query_flags"
    [1]=>
    string(15) "parse_tax_query"
  }
  ["tribe_is_event"]=>
  bool(false)
  ["tribe_is_multi_posttype"]=>
  bool(false)
  ["tribe_is_event_category"]=>
  bool(false)
  ["tribe_is_event_venue"]=>
  bool(false)
  ["tribe_is_event_organizer"]=>
  bool(false)
  ["tribe_is_event_query"]=>
  bool(false)
  ["tribe_is_past"]=>
  bool(false)
  ["request"]=>
  string(695) "SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID FROM wp_posts  INNER JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) JOIN wp_icl_translations t
							ON wp_posts.ID = t.element_id
								AND t.element_type = CONCAT('post_', wp_posts.post_type)  WHERE 1=1  AND ( 
  wp_term_relationships.term_taxonomy_id IN (6)
) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') AND ( ( t.language_code = 'es' AND wp_posts.post_type  IN ('post','page','tribe_events','tribe_venue','tribe_organizer' )  ) OR wp_posts.post_type  NOT  IN ('post','page','tribe_events','tribe_venue','tribe_organizer' )  ) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC LIMIT 0, 5"
  ["posts"]=>
  array(5) {
    [0]=>
    object(WP_Post)#18602 (24) {
      ["ID"]=>
      int(7788)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2017-06-20 10:43:44"
      ["post_date_gmt"]=>
      string(19) "2017-06-20 09:43:44"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(116) "La FDA selecciona a Zepsyre™ (PM1183) de PharmaMar para explorar su potencial desarrollo en cánceres pediátricos"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(96) "fda-chooses-zepsyre-pm1183-from-pharmamar-to-explore-potential-development-for-pediatric-cancers"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-06-20 10:44:52"
      ["post_modified_gmt"]=>
      string(19) "2017-06-20 09:44:52"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(137) "https://www.pharmamar.com/es/2017/06/20/fda-chooses-zepsyre-pm1183-from-pharmamar-to-explore-potential-development-for-pediatric-cancers/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [1]=>
    object(WP_Post)#18603 (24) {
      ["ID"]=>
      int(7781)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2017-06-16 09:01:48"
      ["post_date_gmt"]=>
      string(19) "2017-06-16 08:01:48"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(60) "PharmaMar comercializará PM1183 con el nombre de Zepsyre™"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(66) "pharmamar-will-commercialize-pm1183-with-the-trade-name-of-zepsyre"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-06-16 09:02:49"
      ["post_modified_gmt"]=>
      string(19) "2017-06-16 08:02:49"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(107) "https://www.pharmamar.com/es/2017/06/16/pharmamar-will-commercialize-pm1183-with-the-trade-name-of-zepsyre/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [2]=>
    object(WP_Post)#18604 (24) {
      ["ID"]=>
      int(7773)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2017-06-13 08:42:51"
      ["post_date_gmt"]=>
      string(19) "2017-06-13 07:42:51"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(104) "PharmaMar presenta resultados de ensayos clínicos con lurbinectedina en cáncer de endometrio y de mama"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(109) "pharmamar-announces-encouraging-results-in-clinical-trials-of-lurbinectedin-in-endometrial-and-breast-cancers"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-06-14 08:37:59"
      ["post_modified_gmt"]=>
      string(19) "2017-06-14 07:37:59"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(150) "https://www.pharmamar.com/es/2017/06/13/pharmamar-announces-encouraging-results-in-clinical-trials-of-lurbinectedin-in-endometrial-and-breast-cancers/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [3]=>
    object(WP_Post)#18599 (24) {
      ["ID"]=>
      int(7741)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2017-05-30 14:17:40"
      ["post_date_gmt"]=>
      string(19) "2017-05-30 13:17:40"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(71) "Sylentis inicia un estudio de fase III para el tratamiento del ojo seco"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(74) "sylentis-initiates-a-phase-iii-study-for-the-treatment-of-dry-eye-syndrome"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-05-30 14:18:54"
      ["post_modified_gmt"]=>
      string(19) "2017-05-30 13:18:54"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(115) "https://www.pharmamar.com/es/2017/05/30/sylentis-initiates-a-phase-iii-study-for-the-treatment-of-dry-eye-syndrome/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [4]=>
    object(WP_Post)#18598 (24) {
      ["ID"]=>
      int(7662)
      ["post_author"]=>
      string(1) "7"
      ["post_date"]=>
      string(19) "2017-05-25 16:08:11"
      ["post_date_gmt"]=>
      string(19) "2017-05-25 15:08:11"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(102) "PharmaMar y Eczacıbaşı firman un acuerdo de licencia y comercialización para Aplidin® en Turquía"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(73) "pharmamar-and-eczacibasi-sign-a-licensing-agreement-for-aplidin-in-turkey"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2017-05-25 16:09:00"
      ["post_modified_gmt"]=>
      string(19) "2017-05-25 15:09:00"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(114) "https://www.pharmamar.com/es/2017/05/25/pharmamar-and-eczacibasi-sign-a-licensing-agreement-for-aplidin-in-turkey/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
  }
  ["post"]=>
  object(WP_Post)#18602 (24) {
    ["ID"]=>
    int(7788)
    ["post_author"]=>
    string(1) "7"
    ["post_date"]=>
    string(19) "2017-06-20 10:43:44"
    ["post_date_gmt"]=>
    string(19) "2017-06-20 09:43:44"
    ["post_content"]=>
    string(0) ""
    ["post_title"]=>
    string(116) "La FDA selecciona a Zepsyre™ (PM1183) de PharmaMar para explorar su potencial desarrollo en cánceres pediátricos"
    ["post_excerpt"]=>
    string(0) ""
    ["post_status"]=>
    string(7) "publish"
    ["comment_status"]=>
    string(6) "closed"
    ["ping_status"]=>
    string(6) "closed"
    ["post_password"]=>
    string(0) ""
    ["post_name"]=>
    string(96) "fda-chooses-zepsyre-pm1183-from-pharmamar-to-explore-potential-development-for-pediatric-cancers"
    ["to_ping"]=>
    string(0) ""
    ["pinged"]=>
    string(0) ""
    ["post_modified"]=>
    string(19) "2017-06-20 10:44:52"
    ["post_modified_gmt"]=>
    string(19) "2017-06-20 09:44:52"
    ["post_content_filtered"]=>
    string(0) ""
    ["post_parent"]=>
    int(0)
    ["guid"]=>
    string(137) "https://www.pharmamar.com/es/2017/06/20/fda-chooses-zepsyre-pm1183-from-pharmamar-to-explore-potential-development-for-pediatric-cancers/"
    ["menu_order"]=>
    int(0)
    ["post_type"]=>
    string(4) "post"
    ["post_mime_type"]=>
    string(0) ""
    ["comment_count"]=>
    string(1) "0"
    ["filter"]=>
    string(3) "raw"
  }
}

Otras salas de prensa del Grupo

Ciencia e Innovación

Nuestro fuerte compromiso con la investigación oncológica traslacional, junto con nuestro conocimiento de la biodiversidad procedente de los océanos, nos sitúan a la cabeza de la biotecnología marina.

Sala de Prensa

Si necesitas información sobre la actividad de la compañía, resultados de ensayos clínicos, imágenes corporativas o incluso archivos multimedia, accede a la sala de prensa.